AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...
Drug
Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...
Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program
Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...
Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...
Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...
GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...
Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...
Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study
Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...
Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy
A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...
Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China
The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...